doi: 10.1038/s41366-025-01788-4.
Epub 2025 Apr 16.
Expanding applications of GLP-1 therapies: a careful view
Affiliations
- PMID: 40240468
- DOI: 10.1038/s41366-025-01788-4
Item in Clipboard
Expanding applications of GLP-1 therapies: a careful view
Int J Obes (Lond).
2025 Jul.
No abstract available
Conflict of interest statement
Competing interests: The authors declare no competing interests.
Similar articles
-
Exposure to GLP-1 Receptor Agonist and Bariatric Surgery Use on Obesity Policy Support.Ann Behav Med. 2024 Nov 16;58(12):857-862. doi: 10.1093/abm/kaae063. Ann Behav Med. 2024. PMID: 39427238 Clinical Trial.
-
Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21. J Clin Pharm Ther. 2012. PMID: 22436069
-
New onset diabetic retinopathy with glucagon-like peptide-1 receptor agonists: A case report.J Am Pharm Assoc (2003). 2025 Jul 2:102475. doi: 10.1016/j.japh.2025.102475. Online ahead of print. J Am Pharm Assoc (2003). 2025. PMID: 40609682
-
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol.Res Sq [Preprint]. 2025 May 26:rs.3.rs-6666196. doi: 10.21203/rs.3.rs-6666196/v1. Res Sq. 2025. PMID: 40502777 Free PMC article. Preprint.
-
Impact of GLP-1 receptor agonist-based therapies on cardiovascular and renal outcomes in diabetic and non-diabetic patients with CKD.Diabetol Metab Syndr. 2025 Jul 2;17(1):247. doi: 10.1186/s13098-025-01831-4. Diabetol Metab Syndr. 2025. PMID: 40605083 Free PMC article. Review.
Cited by
-
Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment.Nutrients. 2025 Jul 21;17(14):2382. doi: 10.3390/nu17142382. Nutrients. 2025. PMID: 40733007 Free PMC article. Review.
-
Diet and Muscle Metabolism.Nutrients. 2025 May 20;17(10):1727. doi: 10.3390/nu17101727. Nutrients. 2025. PMID: 40431466 Free PMC article.
References
-
- Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13:15–28. - PubMed
-
- Jastreboff, Roux AM, le CW, Stefanski A, Aronne LJ, Halpern B, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392:958–71. - PubMed
-
- Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol. 2024;12:785–7. - PubMed
-
- Mechanick JI, Butsch WS, Christensen SM, Hamdy O, Li Z, Prado CM, et al. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes Rev. 2025;26:e13841. - PubMed
-
- American Diabetes Association Professional Practice Committee. 13. Older adults: standards of care in diabetes—2025. Diabetes Care. 2024;48:S266–82.
LinkOut - more resources
Full Text Sources
